24th week of 2014 patent applcation highlights part 44 |
Patent application number | Title | Published |
20140161776 | MESENCHYMAL STEM CELLS AND USES THEREFOR - Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount. | 2014-06-12 |
20140161777 | METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES - The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain. | 2014-06-12 |
20140161778 | Method of Pest Control - The present disclose relates to a method for controlling | 2014-06-12 |
20140161779 | METHODS FOR CONTROLLING PEST - Involved is a method for controlling the pest | 2014-06-12 |
20140161780 | COMPOSITIONS AND METHODS FOR AUGMENTING KIDNEY FUNCTION - A protein-rich nutritional food product composed of a probiotic and an edible isolated protein. The probiotic component may comprise | 2014-06-12 |
20140161781 | ZINC-ENRICHED BIOMASS, METHOD FOR THE PREPARATION THEREOF AND PRO-BIOTIC, COSMETIC, DIETARY AND NUTRACEUTIC PRODUCTS COMPRISING THE SAME - The invention relates to a zinc-enriched biomass comprising living or subsequently killed micro-organisms, selected from the group consisting of | 2014-06-12 |
20140161782 | AUGMENTATION OF CELL THERAPY EFFICACY INCLUDING TREATMENT WITH ALPHA 1-3 FUCOSLYTRANSFERASE - Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment. | 2014-06-12 |
20140161783 | Pharmaceutical Liquid Composition of Botulinum Toxin With Improved Stability - Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature. The liquid pharmaceutical composition can be readily prepared because it employs a detergent and an amino acid(s) without a lyophilization process. | 2014-06-12 |
20140161784 | COMPOSITIONS AND METHODS FOR ENHANCING RECOVERY AFTER SURGERY OR AN ATHLETIC PERFORMANCE - The invention provides compositions and dosage forms, e.g., in the form of dietary supplements, such as pills, tablets, beverages, or gels, that enhance recovery after surgery or after an athletic performance. An exemplary composition or dosage form comprises about 5000 IU of vitamin A, about 15 mg of vitamin B1, about 34 mg of vitamin B2, about 25 mg of vitamin B3, about 50 mg of vitamin B5, about 20 mg of vitamin B6, about 90 μg of vitamin B12, about 300 mg of vitamin C, about 500 IU of vitamin D, about 60 IU of vitamin E, about 160 μg of vitamin K1, about 5 μg of vitamin K2, about 300 μg of biotin, about 400 μg of folate, about 30 μg of PABA, about 1 mg of boron, about 200 μg of chromium, about 500 μg of copper, about 150 mg of magnesium, about 5 μg of manganese, about 100 μg of molybdenum, about 135 μg of selenium, about 100 μg of vanadium, about 20 mg of zinc, about 150 μg of iodine, about 1.2 mg of pomegranate extract, about 250 mg of bromelain, and about 250 mg of quercetin. Methods for using the compositions and dosage forms for enhancing recovery after surgery or after an athletic performance are also provided herein. The invention also provides kits comprising a composition or dosage form described herein. | 2014-06-12 |
20140161785 | Verticillin A Inhibition of Histone Methyltransferases - Verticillin A is found to be a potent inhibitor of histone methyltransferases, selective for G9a, GLP, SUV39H1, SUV39H2, MLL1, and NSD2. Methods of using Verticillin A are provided. The Verticillin A can be synthetically produced or it can be isolated from natural sources. Methods if inhibiting one or more histone methyltransferases are provided. In addition, methods are provided for treating diseases or disorders related to overexpression of one or more histone methyltransferases. Exemplary diseases and disorders to be treated include cancer, asthma, HIV, and progeria. | 2014-06-12 |
20140161786 | Therapeutic compositions and related methods - The present invention generally relates to therapeutic compositions for the treatment of mammalian disease and related methods. It more specifically relates to compositions comprising peptides for the treatment of inflammation and methods for delivering the peptides. In one composition aspect, the composition comprises a peptide, and the peptide comprises one or more hexapeptides that are capable of forming fibrils. | 2014-06-12 |
20140161787 | Pharmaceutical Preparation for the Treatment of the Symptoms of Addiction and Method of Diagnosing Same - A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed. | 2014-06-12 |
20140161788 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof - The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. | 2014-06-12 |
20140161789 | THERAPEUTIC VEGETABLE SUBSTANCES - A product containing papain, bromelain or mixtures thereof is intended for use as a medicinal product at a dosage of at least 5000 mg administered for at least one day in a single dose. This dosage relates to papain powder having a titre of 3 U/mg and bromelain powder having a titre of 2 U/mg, and to a patient with a body weight of 55 kg. In the case of variations of the titre and/or of the patient's weight, the dosage must be varied in proportion to said variations. | 2014-06-12 |
20140161790 | ENGINEERED IMMUNOGLOBULINS WITH EXTENDED IN VIVO HALF-LIFE - The present application relates to immunoglobulin compositions with improved half-life, and their application, particularly for therapeutic purposes. | 2014-06-12 |
20140161791 | DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS OF KAWASAKI DISEASE - The present invention provides for compositions and methods for diagnosing and treating Kawasaki disease. More specifically, the proteomes of patients with KD are enriched for the meprin A, filamin B, and filamin C, which serve as biomarkers (and potential therapeutic targets) for KD. Accordingly, detection of these biomarkers, using compositions and methods provided for herein, can inform the therapy delivered to the subject. | 2014-06-12 |
20140161792 | Rhamno-Polysaccharide From Enterococcus Faecium Clonal Complex 17 and Uses Thereof - The present invention relates to a rhamno-polysaccharide antigen from | 2014-06-12 |
20140161793 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI - A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by | 2014-06-12 |
20140161794 | ANTI-VLA-4 ANTIBODIES - This invention relates to alpha-4 binding antibodies, and fragments thereof. | 2014-06-12 |
20140161795 | METHOD FOR TREATING A DISEASE CHARACTERIZED BY INCREASED APPETITE - Insl5 has been found to be orexigenic, i.e. it increases appetite. Insl5, or a derivative or fragment thereof that retains the ability to bind to the GPR100 receptor, or an Insl5 antibody, are useful in therapy, in particular to treat anorexia nervosa, bulimia, cachexia or wasting disease. | 2014-06-12 |
20140161796 | SINGLE CHAIN PROTEINS WITH C-TERMINAL MODIFICATIONS - The invention pertains to an isolated V | 2014-06-12 |
20140161797 | Injectable Non-Aqueous Suspension - The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions. | 2014-06-12 |
20140161798 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS - The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9. | 2014-06-12 |
20140161799 | Therapeutic CD47 Antibodies - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells. | 2014-06-12 |
20140161800 | Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods - The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation. | 2014-06-12 |
20140161801 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as tyrosine kinase inhibitor, wherein R | 2014-06-12 |
20140161802 | SELECTIVE ELIMINATION OF EROSIVE CELLS - The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody. | 2014-06-12 |
20140161803 | CONSTITUTIVELY ACTIVE UPAR VARIANTS AND THEIR USE FOR THE GENERATION AND ISOLATION OF INHIBITORY ANTIBODIES - The invention relates to variants of the urokinase plasminogen activator receptor (uPAR) that display remarkably increased vitronectin (VN) binding activity, possibly caused by a more efficient exposure of the VN binding site. The present invention also refers to antibodies raised against said uPAR variants, able to bind to the VN binding site of uPAR and then acting as inhibitors of uPAR functions, acting as functional antagonists of VN activated-uPAR functions. In the present invention such antibodies are monoclonal, polyclonal, synthetic or recombinant derivatives thereof, as synthetic antibodies (scFv) from phage-display libraries. Antibodies of the invention act as competitive antagonists. | 2014-06-12 |
20140161804 | BISPECIFIC IMMUNOBINDERS DIRECTED AGAINST TNF AND IL-17 - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 2014-06-12 |
20140161805 | Methods for Manipulating Phagocytosis Mediated by CD47 - Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable. | 2014-06-12 |
20140161806 | IMMUNOGENIC SYNTHETIC GLYCOCONJUGATE FOR THE IMMUNOTHERAPY OF MELANOMA - A specific antibody against a compound of formula (I) | 2014-06-12 |
20140161807 | METHODS OF PROMOTING CNS NEURONAL REPAIR BY INHIBITING LRP-1 - This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1). | 2014-06-12 |
20140161808 | ANTIBODIES THAT BIND NOVEL PCSK9 VARIANTS - The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 2014-06-12 |
20140161809 | DIAGNOSTIC AND THERAPEUTIC TARGET - An in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said subject suffering from cancer. The disclosure further relates to antibodies specific for PRELP and their use in diagnosis and therapy as well as a method for indicating a cell as a cancer cell. | 2014-06-12 |
20140161810 | EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES - The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed. | 2014-06-12 |
20140161811 | PLATELET DERIVED GROWTH FACTOR RECEPTOR SUPPORTS CYTOMEGALOVIRUS INFECTIVITY - The disclosure relates generally to compositions and methods useful for inhibiting the infection and propagation of viral particles, particularly members of the Herpesviridae family, and more particularly to cytomegalovirus (CMV). | 2014-06-12 |
20140161812 | IMMUNOREGULATION IN CANCER, CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES - The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases. | 2014-06-12 |
20140161813 | METHODS FOR THE DIAGNOSIS, TREATMENT AND MONITORING OF CANCER - New methods for diagnosing, treating, and monitoring cancer have been developed based on the expression level of markers, such as transcobalamin II (TCII), transcobalamin II receptor (TCIIR), Ki-67, megalin, cubilin, amnionless and/or asialoglycoprotein receptors. For example, a cancer diagnosis can be made by determining the level of TCII, TCIIR, Ki-67, megalin, cubilin, amnionless and/or asialoglycoprotein receptor expression in a test sample from the subject and in a reference sample, and diagnosing the subject as having cancer if the level of expression of transcobalamin II (TCII), transcobalamin II receptor (TCIIR), Ki-67, megalin, cubilin, amnionless, an asialoglycoprotein receptor, or a combination thereof, is statistically significantly different than the respective reference sample. | 2014-06-12 |
20140161814 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof. | 2014-06-12 |
20140161815 | CELL CULTURE METHODS TO REDUCE ACIDIC SPECIES - The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations. | 2014-06-12 |
20140161816 | ANTI- TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods. | 2014-06-12 |
20140161817 | STABLE DUAL VARIABLE DOMAIN IMMUNOGLOBULIN PROTEIN FORMULATIONS - The invention provides stable aqueous formulations comprising an Aqueous Stable Dual Variable Domain Immunoglobulin (AS-DVD-Ig) protein. The invention also provides stable lyophilized formulations comprising a Lyophilized Stable Dual Variable Domain Immunoglobulin (LS-DVD-Ig) protein. | 2014-06-12 |
20140161818 | Bystander Immune Suppression as a Predictor for Response to a Vaccine - The present invention relates to antigen-specific immune regulatory response. Methods for detecting an antigen-specific immune regulatory response, methods for selecting candidate vaccine recipients, and methods for improved vaccination strategies are presented. | 2014-06-12 |
20140161819 | Compositions Comprising Anti-CD38 Antibodies and Lenalidomide - Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits. | 2014-06-12 |
20140161820 | Short-Term Surrogate Test for Investigative Drugs - Provided herein is a short-term myocardial infarction based test for identifying a compound, substance or drug that reduces the risk of myocardial infarction and optionally ischemic heart disease in a test subject(s). Further provided is a method for preventing or treating myocardial infarction using the compound, substance or drug identified. | 2014-06-12 |
20140161821 | TREATMENT WITH ANTI-PCSK9 ANTIBODIES - The present invention concerns dosages for the treatment of human patients susceptible to or diagnosed with a disorder characterized by marked elevations of low density lipoprotein particles in the plasma with a PCSK9 antagonist antibody alone or in combination with a statin. | 2014-06-12 |
20140161822 | ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE - The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. | 2014-06-12 |
20140161823 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AN INFLAMMATION - An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same. | 2014-06-12 |
20140161824 | METHODS AND COMPOSITIONS RELATING TO P62 FOR THE TREATMENT AND PROPHYLAXIS OF CANCER - Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62. | 2014-06-12 |
20140161825 | Methods of Treating Acute Myeloid Leukemia by Blocking CD47 - Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc. | 2014-06-12 |
20140161826 | NON-SELF T-CELL EPITOPE FUSED TO AN ANTIBODY THAT RECOGNISES A TUMOUR-SPECIFIC CELL-SURFACE RECEPTOR AND USES THEREOF - A first composition comprising a ligand part being able to specifically bind to a target, the target being on a diseased cell of an organism, and an epitope part having a non-self epitope, or encoding a non-self epitope, the non-self epitope not naturally being encoded by the organism, wherein the target is internalized after forming a complex with the composition and the non-self epitope is presented on the cell surface of said diseased cell of an organism after internalization. | 2014-06-12 |
20140161827 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention provides combination therapies useful for treating cancer, particularly breast cancer. The invention provides, in various embodiments, methods of treating a cancer, comprising administering to a patient afflicted therewith of an effective amount an immunoconjugate comprising a monoclonal antibody moiety and a first pro-apoptotic drug moiety linked thereto; and administering to the patient an effective amount of a second pro-apoptotic drug. The monoclonal antibody moiety of the immunoconjugate can act to target receptors of hormone-resistant breast cancer cells, such as HER2. Synergistic effects can be seen when the two pro-apoptotic drugs, acting by a common molecular mechanism (vertical modulation) or different molecular mechanisms (horizontal modulation) are administered to patients afflicted by breast cancer, such as hormone-resistant breast cancer. | 2014-06-12 |
20140161828 | BCMA ANTIGEN BINDING PROTEINS - The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates. | 2014-06-12 |
20140161829 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE - The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent). | 2014-06-12 |
20140161830 | AMINE-CONTAINING LIPIDOIDS AND USES THEREOF - Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino moiety of the lipidoids, they are well-suited for the delivery of polynucleotides, in addition to other agents. Nanoparticles containing the inventive lipidoids and polynucleotides have been prepared and have been shown to be effective in delivering siRNA. | 2014-06-12 |
20140161831 | VACCINE FOR A THERAPEUTIC OR A PROPHYLACTIC TREATMENT OF MYASTHENIA GRAVIS - Complementary peptide having at least a sequence complementary to a major immunogenic region of an acetylcholine receptor involved in myasthenia gravis, characterized in that the complementary peptide has at least a sequence SEQ. ID. NO1 with a tryptophan in position 8, carrying at least one optionally substituted hydrocarbon group. Therapeutic composition comprising the Complementary peptide according to the invention and use thereof for manufacturing a vaccine to be used in a therapeutic or prophylactic treatment of myasthenia gravis in mammals. | 2014-06-12 |
20140161832 | COMPOSITION - The present invention relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods. | 2014-06-12 |
20140161833 | NOVEL NEUTRALIZING IMMUNOGEN (NIMIV) OF RHINOVIRUS AND ITS USES FOR VACCINE APPLICATIONS - The invention relates to methods and compositions for preventing or treating human rhinovirus infection. | 2014-06-12 |
20140161834 | Yersinia spp. Polypeptides and Methods of Use - The present invention provides isolated polypeptides isolatable from a | 2014-06-12 |
20140161835 | STAPHYLOCOCCUS AUREUS DIV1B FOR USE AS VACCINE - The invention relates to an antigenic polypeptide referred to as DivIB and variants thereof, vaccines and immunogenic compositions comprising said polypeptide and the use of the vaccines and/or immunogenic compositions in the treatment and prevention of microbial infections. | 2014-06-12 |
20140161836 | CARIOUS TOOTH VACCINE AND PREPARATION METHOD - The present invention provides a vaccine composition for dental caries caused by | 2014-06-12 |
20140161837 | VACCINE ADJUVANT, VACCINE COMPOSITION AND METHOD FOR PREPARING A VACCINE ADJUVANT - The disclosure provides a vaccine adjuvant, including a polysaccharide derived from | 2014-06-12 |
20140161838 | Yersinia spp. Polypeptides and Methods of Use - The present invention provides isolated polypeptides isolatable from a | 2014-06-12 |
20140161839 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN - The present invention relates to a compound of the following general formula (I): R | 2014-06-12 |
20140161840 | COMPOSITION AND METHOD FOR DENTAL REMINERALIZATION - A dental remineralization composition, including a calcium phosphate portion and an organic portion. The calcium phosphate portion is selected from the group including β-TCP and combinations thereof and the β-TCP portion is present in concentrations between about 0.5 ppm to about 10,000 ppm. The organic portion is selected from the group including aspartic acid, glutamic acid, polypeptides, polymers containing functional groups, and combinations thereof and the organic portion is percent in concentrations between about 0.5 ppm to about 10,000 ppm. | 2014-06-12 |
20140161841 | Hybrid Tissue Scaffold For Tissue Engineering - A hybrid tissue scaffold is provided which comprises a porous primary scaffold having a plurality of pores and a porous secondary scaffold having a plurality of pores, wherein the secondary scaffold resides in the pores of the primary scaffold to provide a hybrid scaffold. The pores of the porous primary scaffold may have a pore size in a range of 0.50 mm to 5.0 mm, and the pores of the porous secondary scaffold may have a pore size in a range of 50 μm to 600 μm. The primary scaffold may provide 5% to 30% of a volume of the hybrid scaffold. | 2014-06-12 |
20140161842 | BIORESORBABLE POROUS FILM - A bioresorbable porous film, including a blend mixture of polylactic acid and at least two kinds of polyethylene glycol, wherein the at least two kinds of polyethylene glycol include a first polyethylene glycol, which is in a solid form under ambient temperature and atmospheric pressure, and a second polyethylene glycol, which is in a liquid form under ambient temperature and atmospheric pressure is provided. The film has a porosity of 10%-90%. | 2014-06-12 |
20140161843 | Dynamic Macropore Formation Using Multiple Porogens - Macroporous 3-D tissue engineering scaffold are manufactured by contacting an article comprising multiple distinct macroparticulate porogens distributed within a polymer scaffold, wherein the porogens are selectively and sequentially dissolvable by corresponding biocompatible stimuli. | 2014-06-12 |
20140161844 | CROSSLINKER ENHANCED REPAIR OF CONNECTIVE TISSUES - A protein crosslinker delivery device includes a body and a protein crosslinker held in a synthetic or natural biodegradable polymer. The body, a coating on the body, or an attachment to the body can contain the protein crosslinker holding biodegradable polymer. The release rate of the crosslinker and total amount of crosslinker released can be controlled by varying the concentration of the crosslinker and by varying the composition and structural characteristics of the degradable polymer. Surface eroding, bulk eroding and naturally occurring biodegradable polymers can be used in conjunction with a variety of nontoxic or minimally-toxic protein crosslinking agents. The devices can be used to treat mechanically damaged, deformed, and nutritionally deficient connective or soft tissues such as the knee meniscus, the spinal disc, the cornea, ligaments and tendons, the soft palate, and skin. | 2014-06-12 |
20140161845 | ANTI-BIOFILM COMPOUNDS - The present invention provides non-peptide compounds of formula (I) wherein: X is —(C | 2014-06-12 |
20140161846 | SUNSCREEN WITH COOLING AGENT - A sunscreen formulation and methods for making the same include a sunscreen compound into which is added a cooling agent. The cooling agent will produce a cooling or cooling sensation when experienced by a user of the sunscreen. A controlled release mechanism is used to delay activation of the cooling agent. | 2014-06-12 |
20140161847 | BREATH FRESHENING PRODUCT - An improved method and system for reducing the condition of bad breath is provided. The system is directed to a breath freshening composition which includes a plurality of sugar alcohol carbonated crystals as a delivery medium, to which a vegetable or nut oil, and a zinc based compound for controlling bad breath are added. The composition is prepared by first producing the sugar alcohol carbonated crystals and then adding to said crystals, preferably by spraying, the vegetable or nut oil and the zinc based compound. Additional ingredients may be added to the carbonated crystals, including sugar based alcohols for inhibiting bacterial growth, flavor powders and sweeteners. | 2014-06-12 |
20140161848 | UV PROTECTIVE COSMETIC COMPOSITION - The present invention aims to provide a UV protective cosmetic composition having a high SPF and having a protective effect in a broad wavelength region over UVA and UVB, without undesirable white appearance upon application to the skin. The UV protective cosmetic composition of the present invention comprises (a) 3-15% by mass of one or more UV absorbing agents; (b) 10-22% by mass of zinc oxide with an average particle diameter of 35-80 nm; and optionally (c) 0-0.5% by mass of a white pigment, wherein the SPF of the cosmetic is 30 or greater, and the critical wavelength of the cosmetic is 370 nm or greater. | 2014-06-12 |
20140161849 | Cosmetic Compositions With Near Infra-Red (NIR) Light - Emitting Material And Methods Therefor - Cosmetic or dermatological compositions and substrates, containing a NIR light-emitting material, and methods for stimulating healing and/or regenerative properties in the skin, hair and/or scalp are provided. | 2014-06-12 |
20140161850 | Cosmetic Compositions With Near Infra-Red (NIR) Light - Emitting Material And Methods Therefor - Cosmetic or dermatological compositions and substrates, containing a NIR light-emitting material, and methods for stimulating healing and/or regenerative properties in the skin, hair and/or scalp are provided. | 2014-06-12 |
20140161851 | Cosmetic Compositions With Near Infra-Red (NIR) Light - Emitting Material And Methods Therefor - Cosmetic or dermatological compositions and substrates, containing a NIR light-emitting material, and methods for stimulating healing and/or regenerative properties in the skin, hair and/or scalp are provided. | 2014-06-12 |
20140161852 | NANOPARTICLE DENTAL COMPOSITION AND METHOD OF MAKING - Disclosed are compositions and methods for reducing dentin hypersensitivity. Also disclosed are compositions containing calcium fluoride nanoparticles. | 2014-06-12 |
20140161853 | Non-Irritating Benzoyl Peroxide - A method of making crystalline benzoyl peroxide particles having a particle size no greater than 25 microns and formed by wet milling in the absence of solvents and wherein the crystalline benzoyl peroxide is not irritating to the skin. A method of making a therapeutic or cosmetic composition comprising a water-based gel containing the crystalline benzoyl peroxide. | 2014-06-12 |
20140161854 | AMPHIPHILIC ENTITY NANOPARTICLES - The present invention provides nanoparticle compositions comprising AE nanoparticles. The present invention provides AE nanoparticles comprising one or more amphiphilic entities and pharmaceutical compositions comprising AE nanoparticles. The present invention provides methods of manufacturing AE nanoparticles. The present invention provides methods of delivering a biologically active agent to a subject by administering AE nanoparticles containing a biologically active agent to a subject. | 2014-06-12 |
20140161855 | COSMETIC WITH ENHANCED COLLAGEN I SYNTHESIS - A cosmetic including two different systems for procurement of actives in the human skin and enhancing the collagen I synthesis. The cosmetic with enhanced collagen I synthesis can include 0.001 to 2% by weight, related to the total weight of the cosmetic, of a first retinol-containing system including retinol encapsulated in a chitosan and carboxymethyl cellulose shell, 0.001 to 3.5% by weight, related to the total weight of the cosmetic, of a second retinol-containing system including cationic liposomes composed of phospholipids and with a quaternary fatty acid monoamine with C | 2014-06-12 |
20140161856 | Retention of PBO in Polymer Matrices by Phthalocyanines - By incorporating PBO and phtalocyanine in a polymeric matrix, the surface concentration of the PBO after migration to the surface is reduced relatively to a matrix without phtalocyanine. This can be used to control the migration of PBO and retain PBO for a long-lasting effect. | 2014-06-12 |
20140161857 | INSECTICIDAL APPARATUS AND METHODS - Insecticidal apparatus and methods are provided for controlling or managing insect pests and ectoparasites. An apparatus for administering an insecticidal compound to a subject can include a material for absorbing an insecticidal compound and an insecticidal compound. An insecticidal apparatus can include an attachment element for attaching the apparatus to a desired location. Insect pests or ectoparasites can be controlled or managed on subjects or animals coming into contact with or in proximity to an insecticidal apparatus as disclosed herein. | 2014-06-12 |
20140161858 | Multigraft Copolymers as Superelastomers - Thermoplastic elastomer compositions are described comprising multigraft copolymers. The multigraft copolymers can comprise a rubbery polymeric backbone and a plurality of glassy polymeric side chains, each attached at one of a plurality of branch points randomly spaced along the backbone. The copolymer materials have high tensile strength, high strain at break, and low residual strain after elongation. The compositions can be used as adhesives and in a wide variety of high tech, medical, and commodity applications. | 2014-06-12 |
20140161859 | DERMAL MICRO-ORGANS, METHODS AND APPARATUSES FOR PRODUCING AND USING THE SAME - Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. | 2014-06-12 |
20140161860 | Implantable Polymeric Device for Sustained Release of Buprenorphine - The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine. | 2014-06-12 |
20140161861 | Methods And Compositions For The Treatment Of Open And Closed Wound Spinal Cord Injuries - Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury. | 2014-06-12 |
20140161862 | ABSORBABLE COATING FOR IMPLANTABLE DEVICE - The present invention provides an absorbable coating for an implantable device and the methods of making and using the same. | 2014-06-12 |
20140161863 | DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM - A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive. | 2014-06-12 |
20140161864 | ACTIVE FORMULATION FOR USE IN FEED PRODUCTS - Invention pertains to a free-flowing particulate powder including 2-90 wt. % of an active compound on a carrier, wherein the carrier has a D(v,0.1) of at least 100 microns, with the active compound being selected from lactylate in accordance with formula (1), Formula (1): R2-COO—[—CH(CH3)-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a glycolylate of formula (2), Formula (2): R2-COO—[—CH2-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof a lactate ester of formula (3), Formula (3): HO—CH(CH3)-COO—R2 and/or a glycolic acid ester of formula (4), Formula (4): HO—CH2-COO—R2 wherein in the above formulae R1 is selected from H, n stands for an integer with a value of 1-10, and R2 stands for a C1-C35 alkyl or alkenyl chain which may be branched or unbranched. The powder allows easy provision of the active compound to feed compositions. | 2014-06-12 |
20140161865 | PATCH AND METHOD FOR PRODUCING THE SAME - A method for producing a patch having a high skin penetrability and a high pharmaceutical physical properties such as adhesion and cohesiveness, and a long-term storability. The patch is produced by first obtaining an adhesive agent layer composition containing oxybutynin and/or salt thereof as a drug, an acrylic-based polymer and/or a rubber-based polymer as an adhesive base agent, liquid paraffin, an organic acid, and a tackifier; heating the adhesive agent layer composition at a temperature in a range from a melting point of the drug to a temperature higher than the melting point by 10° C. for 2 to 24 hours; and slowly cooling the heated adhesive agent layer composition to obtain the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form. | 2014-06-12 |
20140161866 | STRUCTURES AND METHODS FOR DELIVERING TOPICAL COMPOSITIONS - A system for topically administering a chemical agent to a human body. The chemical agent may be mixed with a carrier and the form a tangible application device. The carrier may be compound or a physical structure such as an absorbent material. | 2014-06-12 |
20140161867 | METHOD OF TOPICALLY APPLYING GLYCOPYRROLATE SOLUTION USING ABSORBENT PAD TO REDUCE SWEATING - This invention relates to a convenient and safe product and method of applying glycopyrrolate topically in order to reduce excessive sweating in localized areas for those who suffer from this condition. This invention also relates to combining oral and topical delivery of glycopyrrolate to reduce excessive sweating and minimize side effects. This invention also relates to a convenient and safe product and method of applying glycopyrrolate topically to areas of compensatory sweating after endoscopic thoracic sympathectomy. | 2014-06-12 |
20140161868 | TRANSDERMAL DELIVERY SYSTEM KIT - A transdermal delivery kit that enhances the efficacy of a topical drug includes at least one drug dispensing device, a lipophilic base, a hydrophilic base, a lipid-soluble active ingredient, a water-soluble active ingredient, a first container for mixing the lipophilic base with the lipid-soluble active ingredient to form a first compound, a second container for mixing the hydrophilic base with the water-soluble active ingredient to form a second compound, a mixing member, and instructions for compounding the lipophilic base with the lipid-soluble active ingredient to form the first compound, compounding the hydrophilic base with the water-soluble active ingredient to form the second compound, and mixing the first compound and the second compound to form a transdermal pharmaceutical delivery system capable of delivering a drug to the dermal layer of the skin. | 2014-06-12 |
20140161869 | MicroRNA Fingerprints During Human Megakaryocytopoiesis - Described herein are compositions and methods of decreasing expression of MAFB in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a MAFB gene product where an effective amount of at least one miR-130a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the MAFB gene product in the subject. | 2014-06-12 |
20140161870 | Antibody Specific for CD22 and Methods of Use Thereof - The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided. | 2014-06-12 |
20140161871 | SKIN PERMEATING AND CELL ENTERING (SPACE) PEPTIDES AND METHODS OF USE THEREOF - The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells. | 2014-06-12 |
20140161872 | COMPOSITIONS AND METHODS FOR TREATMENT - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2014-06-12 |
20140161873 | MODIFIED POLYNUCLEOTIDES ENCODING ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2014-06-12 |
20140161874 | PROCESS OF PREPARATION AND USES OF PLASMA MEMBRANE VESICLES EXTRACTED FROM PLANTS ENRICHED IN MEMBRANE TRANSPORT PROTEINS - The invention relates to a method for obtaining membrane vesicles enriched in membrane transport proteins of plant origin, for cosmetic or therapeutic use, which can contain other substances, such as natural bioactive compounds. Preferably, said vesicles are obtained from plants of the Brassicaceae (cruciferae) family. In addition, the invention relates to a method for increasing these proteins of plant origin. | 2014-06-12 |
20140161875 | ANTIBODIES TO PHOSPHORYLATED TAU AGGREGATES - This invention concerns affinity tools for oligomeric forms of tau protein. It relates to the field of neurodegeneration, more particularly to the field of tau-related diseases and tauopathy. The invention provides novel tau antibodies and antibody fragments, nucleic acids encoding such antibodies and antibody fragments, cell lines producing such antibodies and antibody fragments, antibody compositions, and kits for the detection of aggregated tau and for the diagnosis of diseases involving aggregated tau. The invention further provides methods for the detection of aggregated tau, for the diagnosis of diseases involving aggregated tau, and for the identification of compositions interfering with the formation and/or stability of tau aggregates. | 2014-06-12 |